Clinical Trial Update: Long-Term Organ Damage: Anifrolumab Versus Real-World Standard of Care in Adult Patients With Active Systemic Lupus Erythematosus

View source ↗

Summary

A completed trial compares anifrolumab to real-world standard of care in adults with active systemic lupus erythematosus, focusing on long-term organ damage.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• SAPHNELO (ANIFROLUMAB-FNIA)

Snippet

Sponsor: AstraZeneca | Conditions: Long-Term Organ Damage in Adult Patients With Active Systemic Lupus Erythematosus | Status: COMPLETED